Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trimeris (TRMS) -- Ignore unavailable to you. Want to Upgrade?

To: Ben Wa who wrote (87)	9/12/2000 5:50:37 PM
From: Pluvia	Read Replies (1) \| Respond to of 108

you have an interesting conclusion. the analysis is IMO, overly simplistic, however you are entitled to your opinion. I don't think the question is overly difficult. 1. A study that mistakenly uses two variables cannot draw accurate conclusions. 2. The T-20 trial using a Genotype selected anti-HIV cocktail and T-20 used two variables - thus you don't know which variable caused the positive results. This point is proven by the results of the Durant study, which mimic the best T-20 results by using only the Genotype selected anti-HIV cocktail. findarticles.com 3. Clearly this study design was flawed. 4. Furthermore, Wall Street incorrectly drew the conclusion the trial success should be attributed to T-20 when it is clear from the Durant study, that the other anti-HIV drugs used in the T-20 study played a significant role. I suggest you read the Durant study and re-evaluate.